Singapore markets closed
Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
64,221.51 +2,132.66 (+3.43%) CMC Crypto 200
1,371.97 +59.34 (+4.52%)
AbCellera Biologics Inc. (ABCL)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 1.13B |
| Enterprise value | 451.33M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 29.47 |
| Price/book (mrq) | 0.98 |
| Enterprise value/revenue | 11.87 |
| Enterprise value/EBITDA | -2.35 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.36 |
| 52-week change 3 | -46.03% |
| S&P500 52-week change 3 | 20.07% |
| 52-week high 3 | 8.0500 |
| 52-week low 3 | 3.7900 |
| 50-day moving average 3 | 4.7094 |
| 200-day moving average 3 | 5.1880 |
Share statistics
| Avg vol (3-month) 3 | 1.35M |
| Avg vol (10-day) 3 | 1.07M |
| Shares outstanding 5 | 292.78M |
| Implied shares outstanding 6 | 292.78M |
| Float 8 | 191.76M |
| % held by insiders 1 | 28.09% |
| % held by institutions 1 | 43.65% |
| Shares short (28 Mar 2024) 4 | 23.59M |
| Short ratio (28 Mar 2024) 4 | 17.89 |
| Short % of float (28 Mar 2024) 4 | 11.18% |
| Short % of shares outstanding (28 Mar 2024) 4 | 8.06% |
| Shares short (prior month 29 Feb 2024) 4 | 22.78M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -719.61% |
Management effectiveness
| Return on assets (ttm) | -9.79% |
| Return on equity (ttm) | -12.27% |
Income statement
| Revenue (ttm) | 38.02M |
| Revenue per share (ttm) | 0.13 |
| Quarterly revenue growth (yoy) | -57.40% |
| Gross profit (ttm) | N/A |
| EBITDA | -212.81M |
| Net income avi to common (ttm) | -146.4M |
| Diluted EPS (ttm) | -0.5100 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 760.59M |
| Total cash per share (mrq) | 2.6 |
| Total debt (mrq) | 77.38M |
| Total debt/equity (mrq) | 6.72% |
| Current ratio (mrq) | 7.33 |
| Book value per share (mrq) | 3.96 |
Cash flow statement
| Operating cash flow (ttm) | -43.88M |
| Levered free cash flow (ttm) | -102.96M |
© 2024 Yahoo. All rights reserved.